Anebulo Pharmaceuticals News

Anebulo Pharmaceuticals | 10-Q: Quarterly report

SEC announcementMay 15 21:26 · Announcements

Anebulo Pharmaceuticals Q3 EPS $(0.06) Beats $(0.12) Estimate

Anebulo Pharmaceuticals (NASDAQ:ANEB) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.12) by 50 percent. This is a 45.45 percent increase over losses of

BenzingaMay 15 12:07

Anebulo Pharmaceuticals 3Q Loss/Shr 6c >ANEB

Anebulo Pharmaceuticals 3Q Loss/Shr 6c >ANEB

Dow JonesMay 15 12:07

Press Release: Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates

Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates AUSTIN, Texas--(BUSINESS WIRE)--May 15, 2024-- Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a cli

Dow JonesMay 15 12:05

We Think Anebulo Pharmaceuticals (NASDAQ:ANEB) Needs To Drive Business Growth Carefully

Yahoo FinanceApr 15 05:03

Anebulo Pharmaceuticals: Strong Buy Rating Amid Promising Clinical Advances and Rapid FDA Track

TipRanksFeb 15 13:25

New Debt & Financing Risk for Anebulo Pharmaceuticals, Inc. – What's the Latest?

TipRanksFeb 15 00:02

Substance Use Disorder Company Narrows Q2 Net Loss, Reports Progress On Cannabinoid Intoxication Drug

The biopharmaceutical company Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) reported its second quarter financial results on Tuesday for the three months ended Dec. 31, 2023,The company's primary focus

BenzingaFeb 14 10:37

Anebulo Pharmaceuticals Announces Richie Cunningham As Chief Executive Officer

Anebulo Pharmaceuticals Announces Richie Cunningham As Chief Executive Officer

BenzingaFeb 13 15:44

Anebulo Pharmaceuticals Q2 EPS $(0.11) Misses $(0.10) Estimate

Anebulo Pharmaceuticals (NASDAQ:ANEB) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.10) by 10 percent. This is a 26.67 percent increase over losses

BenzingaFeb 13 15:43

Anebulo Pharmaceuticals 2Q Loss/Shr 11c >ANEB

Anebulo Pharmaceuticals 2Q Loss/Shr 11c >ANEB

Dow JonesFeb 13 15:07

Press Release: Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates AUSTIN, Texas--(BUSINESS WIRE)--February 13, 2024-- Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB),

Dow JonesFeb 13 15:05

Anebulo Pharmaceuticals Filed U.S. Patent Application #20240010617: Crystalline Forms Of A Cannabinoid Receptor Type 1 (Cb1) Modulator And Methods Of Use And Preparation Thereof

Anebulo Pharmaceuticals Filed U.S. Patent Application #20240010617: Crystalline Forms Of A Cannabinoid Receptor Type 1 (Cb1) Modulator And Methods Of Use And Preparation Thereof

BenzingaJan 11 05:42

Buy Recommendation for Anebulo Pharmaceuticals: Promising Financial Outlook and Potential Breakthrough in Acute Cannabis Intoxication Treatment

TipRanksNov 16, 2023 14:55

Anebulo Pharmaceuticals GAAP EPS of -$0.10 Beats by $0.02

Seeking AlphaNov 15, 2023 07:49

Anebulo Pharmaceuticals Q1 EPS $(0.10) Beats $(0.12) Estimate

Anebulo Pharmaceuticals (NASDAQ:ANEB) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.12) by 16.67 percent. This is a 9.09 percent increase over losses

BenzingaNov 14, 2023 15:59

Rising Cannabis Hospitalizations and Leadership Transition Boost Anebulo Pharmaceuticals' Outlook: A Buy Rating Analysis

TipRanksOct 26, 2023 12:26

12 Health Care Stocks Moving In Tuesday's Intraday Session

GainersNkarta (NASDAQ:NKTX) shares moved upwards by 122.3% to $3.29 during Tuesday's regular session. Nkarta's stock is trading at a volume of 55.0 million shares as of 13:30 EST. This is 13383.6% of

BenzingaOct 17, 2023 12:31

Purple Biotech, Nuwellis Among Healthcare Movers

Seeking AlphaOct 17, 2023 09:00

MNTS, OMER and PIXY Among Mid-day Movers

Seeking AlphaOct 16, 2023 12:36